Fulgent Genetics Financial Results
Fulgent Genetics reported Q3 2026 revenue of $90.4 million, representing 8% year-over-year growth. The company reported a GAAP loss of $13.2 million and maintained its full-year 2026 revenue guidance of $330 million to $340 million. Management highlighted momentum in their therapeutics pipeline and the integration of AI into laboratory services workflows.
- Term
- Q3 2026
“We are encouraged by the momentum in our therapeutics pipeline, with both FID-007 and FID-022 using our nano-drug delivery platform. In our laboratory services business, we continue to integrate AI into our workflow as utilization scales and reliability substantially increases. We expect to continue to expand our AI portfolio to drive further improvements to efficiency and quality.”
Ming Hsieh, Chairman of the Board of Directors and Chief Executive Officer
“We are pleased with our third quarter results, driven by the improvement in our collection rates. We made great progress to address the billing system issue and remain confident in our outlook for the remainder of the year.”
Paul Kim, Chief Financial Officer